Cyberonics builds epilepsy leadership with NeuroVista deal
This article was originally published in Clinica
Neuromodulation firm Cyberonics (Houston, Texas) has strengthened its position as leader in medical devices for treating epilepsy by executing a licensing deal with NeuroVista. The deal gives Cyberonics access to technology and patents that allow it to develop an implantable pulse generator for stimulating the vagus nerve in response to EEG-based detection of a seizure. Seattle, Washington-based NeuroVista specialises in implantable neurotechnology for the management and treatment of epilepsy. Financial terms of the deal were not revealed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals